Determination of doravirine in human plasma using liquid–liquid extraction and HPLC

Determination of doravirine in human plasma using liquid–liquid extraction and HPLC–MS/MS

Published:2019-08 Issue:16 Volume:11 Page:1495-1508
ISSN:1757-6180
Container-title:Bioanalysis
language:en
Short-container-title:Bioanalysis

Author:

Desai Rajesh¹,Roadcap Brad¹,Goykhman Dina¹,Woolf Eric¹

Affiliation:

1. Department of Pharmacokinetics, Pharmacodynamics & Drug Metabolism, MRL, Merck & Co., Inc., West Point, PA 19486-0004, USA

Abstract

Aim: A method to quantitate doravirine (MK-1439) in human plasma has been developed to support human clinical trials designed to evaluate the safety, pharmacokinetics and efficacy of the compound. Methodology & results: The analyte was extracted using liquid–liquid extraction, separated on a reverse phase HPLC column, and detected on an API-4000 mass spectrometer using a Turbo-Ion spray source in positive ionization mode coupled with multiple reaction monitoring mode was used for quantification. The dynamic range for the assay was 0.02–10 ng/ml using 100 μl of human plasma. Conclusion: The assay was found to be sensitive, selective and reproducible and applied to support the doravirine clinical development program.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Link

https://www.future-science.com/doi/pdf/10.4155/bio-2019-0116

Reference13 articles.

1. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects

2. Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability

3. In VitroResistance Selection with Doravirine (MK-1439), a Novel Nonnucleoside Reverse Transcriptase Inhibitor with Distinct Mutation Development Pathways

4. Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations

5. A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HPTLC METHOD FOR SIMULTANEOUS ESTIMATION OF LAMIVUDINE, TENOFOVIR DISOPROXIL FUMARATE, AND DORAVIRINE;International Journal of Pharmacy and Pharmaceutical Sciences;2023-09-01

2. Validation of an LC-MS/MS assay for the simultaneous determination of bictegravir, doravirine, and raltegravir in human plasma;Journal of Pharmaceutical and Biomedical Analysis;2022-10

3. Development and Validation of Stability-indicating assay UHPLC Method for Simultaneous analysis of Dolutegravir, Lamivudine and Tenofovir disoproxil fumarate in Bulk and Pharmaceutical Formulation;Research Journal of Pharmacy and Technology;2022-09-28

4. Validated Stability-Indicating Assay UHPLC Method for Simultaneous Estimation of Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate in Pure Material and Pharmaceutical Matrix;Biointerface Research in Applied Chemistry;2022-01-22

5. Bioanalytical Method Development and Validation of Doravirine, Lamavudine and Tenofovir Disoproxil Fumarate using HPLC in Human Plasma;Research Journal of Pharmacy and Technology;2021-08-06